ADC ID	DRG0DEGEG
ADC Name	Vobramitamab duocarmazine
Synonyms	vobramitamab duocarmazine; MGC018    Click to Show/Hide
Organization	MacroGenics (Originator);Byondis
Drug Status	Phase 2 (discontinued)
Drug-to-Antibody Ratio	2.7
Structure
	3D MOL			2D MOL
Antibody Name	Vobramitamab					Antibody Info
Antigen Name	CD276 antigen (CD276); Hepatocyte growth factor receptor (MET)					Antigen Info
Payload Name	Seco-DUBA					Payload Info
Therapeutic Target	Human deoxyribonucleic acid (hDNA)					Target Info
Linker Name	Mal-PEG2-Val-Cit-PABA-Cyclization Spacer					Linker Info
Conjugate Type	Random Cysteines
Combination Type	duocarmazine

Bystander Killing Effect	Description	Reference
yes	To assess the potential for bystander killing, an in vitro coculture experiment was conducted in which Hs700T/B7-H3 KO cells, engineered to express stabilized red fluorescent protein (Hs700T/B7-H3 KO/RFP), were cultured alone, or in the presence of progressively larger amounts of unlabeled parental Hs700T cells. The cultures were incubated with MGC018 and the number of viable RFP-labeled cells (only Hs700T/B7-H3 KO/RFP cells were visible) were monitored by time-lapse fluorescent microscopy over a period of 5 days. As shown in Fig. 1B, treatment with MGC018 had no effect on the viability of Hs700T/B7-H3 KO/RFP cells when cultured alone (gray bar vs. white bar). Conversely, MGC018 treatment led to killing of greater than 90% of parental Hs700T cells. However, in the coculture setting, bystander killing of Hs700T/B7-H3 KO/RFP cells was observed, with the magnitude of bystander killing increasing as the number of parental Hs700T cells increased (orange bars).    Click to Show/Hide	[1]
yes	To assess the potential for bystander killing, an in vitro coculture experiment was conducted in which Hs700T/B7-H3 KO cells, engineered to express stabilized red fluorescent protein (Hs700T/B7-H3 KO/RFP), were cultured alone, or in the presence of progressively larger amounts of unlabeled parental Hs700T cells. The cultures were incubated with MGC018 and the number of viable RFP-labeled cells (only Hs700T/B7-H3 KO/RFP cells were visible) were monitored by time-lapse fluorescent microscopy over a period of 5 days. As shown in Fig. 1B, treatment with MGC018 had no effect on the viability of Hs700T/B7-H3 KO/RFP cells when cultured alone (gray bar vs. white bar). Conversely, MGC018 treatment led to killing of greater than 90% of parental Hs700T cells. However, in the coculture setting, bystander killing of Hs700T/B7-H3 KO/RFP cells was observed, with the magnitude of bystander killing increasing as the number of parental Hs700T cells increased (orange bars).    Click to Show/Hide	[1]
yes	To assess the potential for bystander killing, an in vitro coculture experiment was conducted in which Hs700T/B7-H3 KO cells, engineered to express stabilized red fluorescent protein (Hs700T/B7-H3 KO/RFP), were cultured alone, or in the presence of progressively larger amounts of unlabeled parental Hs700T cells. The cultures were incubated with MGC018 and the number of viable RFP-labeled cells (only Hs700T/B7-H3 KO/RFP cells were visible) were monitored by time-lapse fluorescent microscopy over a period of 5 days. As shown in Fig. 1B, treatment with MGC018 had no effect on the viability of Hs700T/B7-H3 KO/RFP cells when cultured alone (gray bar vs. white bar). Conversely, MGC018 treatment led to killing of greater than 90% of parental Hs700T cells. However, in the coculture setting, bystander killing of Hs700T/B7-H3 KO/RFP cells was observed, with the magnitude of bystander killing increasing as the number of parental Hs700T cells increased (orange bars).    Click to Show/Hide	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	47201.1	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Human sera.	[1]
Area Under the Concentration-Time Curve (AUC)	35015.27	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Cynomolgus Monkey sera.	[1]
Area Under the Concentration-Time Curve (AUC)	614.72	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CD-1 Nude Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	11371.21	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CES1 KO Mouse sera.	[1]
Time to Maximum Concentration (Tmax)	1.2	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg.	[1]
Maximum Observed Concentration (Cmax)	26.4	ug/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	659	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	663	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUCinf.	[1]
Time to Maximum Concentration (Tmax)	1.8	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg.	[1]
Maximum Observed Concentration (Cmax)	92	ug/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	3179	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	3210	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUCinf.	[1]
Time to Maximum Concentration (Tmax)	1.9	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg.	[1]
Maximum Observed Concentration (Cmax)	181.5	ug/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	8950	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9032	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUCinf.	[1]
Time to Maximum Concentration (Tmax)	1.2	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg.	[1]
Maximum Observed Concentration (Cmax)	310.9	ug/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	14894	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	15075	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUCinf.	[1]
Time to Maximum Concentration (Tmax)	0.5	h	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg.	[1]
Maximum Observed Concentration (Cmax)	47.2	ug/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	2908.9	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	8848	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUCinf.	[1]
Time to Maximum Concentration (Tmax)	0.5	h	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg.	[1]
Maximum Observed Concentration (Cmax)	31.4	ug/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	3689.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6660.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUCinf.	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	47201.1	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Human sera.	[1]
Area Under the Concentration-Time Curve (AUC)	35015.27	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Cynomolgus Monkey sera.	[1]
Area Under the Concentration-Time Curve (AUC)	614.72	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CD-1 Nude Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	11371.21	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CES1 KO Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	659	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	663	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUCinf.	[1]
Volume of Distribution (Vd)	81.4	mL/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	3179	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	3210	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUCinf.	[1]
Volume of Distribution (Vd)	66.3	mL/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	8950	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9032	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUCinf.	[1]
Volume of Distribution (Vd)	56.8	mL/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	14894	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	15075	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUCinf.	[1]
Volume of Distribution (Vd)	64.6	mL/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	2908.9	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	8848	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	3689.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6660.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUCinf.	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	47201.1	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Human sera.	[1]
Area Under the Concentration-Time Curve (AUC)	35015.27	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Cynomolgus Monkey sera.	[1]
Area Under the Concentration-Time Curve (AUC)	614.72	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CD-1 Nude Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	11371.21	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CES1 KO Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	659	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	663	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	3179	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	3210	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	8950	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9032	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	14894	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	15075	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	2908.9	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	8848	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	3689.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6660.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUCinf.	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	47201.1	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Human sera.	[1]
Area Under the Concentration-Time Curve (AUC)	35015.27	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the Cynomolgus Monkey sera.	[1]
Area Under the Concentration-Time Curve (AUC)	614.72	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CD-1 Nude Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	11371.21	ug*h/mL	Summary of total and conjugated antibody pharmacokinetic parameters from noncompartmental analysis following incubation in the CES1 KO Mouse sera.	[1]
Area Under the Concentration-Time Curve (AUC)	659	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	663	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg, AUCinf.	[1]
Elimination Half-Life (t1/2)	78.1	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg.	[1]
Clearance (CL)	1.53	mL/h/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 1mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	3179	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	3210	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg, AUCinf.	[1]
Elimination Half-Life (t1/2)	84.5	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg.	[1]
Clearance (CL)	0.95	mL/h/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 3 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	8950	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9032	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg, AUCinf.	[1]
Elimination Half-Life (t1/2)	67.9	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg.	[1]
Clearance (CL)	0.68	mL/h/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 6 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	14894	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	15075	ug*h/mL	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg, AUCinf.	[1]
Elimination Half-Life (t1/2)	74.1	h	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg.	[1]
Clearance (CL)	0.67	mL/h/kg	Summary of conjugated antibody pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in cynomolgus monkeys, 10 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	2908.9	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	8848	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg AUCinf.	[1]
Elimination Half-Life (t1/2)	424.5	h	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg.	[1]
Clearance (CL)	0.57	mL/h/kg	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in CD1 nude mice, 5 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	3689.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6660.2	ug*h/mL	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg AUCinf.	[1]
Elimination Half-Life (t1/2)	205.1	h	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg.	[1]
Clearance (CL)	0.75	mL/h/kg	Summary of ADC pharmacokinetic parameters from noncompartmental analysis of first MGC018 dose data in SCID/CES1c knock out mice, 5 mg/kg.	[1]

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05551117	PHASE2	A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Undisclosed	NCT06227546	PHASE2	A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Undisclosed	NCT05551117	Phase 2	A phase 2, randomized, open-label, study of two dose levels of obramitamab duocarmazine in participants with metastatic castration-resistant prostate cancer.
Undisclosed	NCT03729596	Phase 1/2	A phase 1/2, first-in-human, open-label, dose-escalation study of MGC018 (anti-B7-H3 antibody drug conjugate) alone and in combination with MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors.    Click to Show/Hide
Undisclosed	NCT05293496	Phase 1	A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with checkpoint inhibitor in participants with advanced solid tumors.

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	≈ 96.1	%	Pancreatic cancer PDX model (PDX: PDX-PAX-13565)
Tumor Growth Inhibition value (TGI)	≈ 97.6	%	Head and neck cancer PDX model
Tumor Growth Inhibition value (TGI)	≈ 98.2	%	Triple-negative breast cancer PDX model

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 22.4	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 30.1	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 42.9	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 43.9	%	MDA-MB-468 Luc cells	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 59.3	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 62.7	%	MDA-MB-468 Luc cells	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 62.8	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 66.5	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 71.9	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 76.3	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 76.6	%	A375.S2 cells	Amelanotic melanoma
Tumor Growth Inhibition value (TGI)	≈ 82.8	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 83.9	%	A375.S2 cells	Amelanotic melanoma
Tumor Growth Inhibition value (TGI)	≈ 87.5	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 88.8	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 90.5	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 91.4	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 94.6	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 96.7	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 97	%	MDA-MB-468 Luc cells	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 97.6	%	PA-1 cells	Ovarian mixed germ cell tumor
Tumor Growth Inhibition value (TGI)	≈ 97.9	%	MDA-MB-468 Luc cells	Breast adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 98.1	%	A375.S2 cells	Amelanotic melanoma
Tumor Growth Inhibition value (TGI)	≈ 98.6	%	Calu-6 cells	Lung adenocarcinoma
Tumor Growth Inhibition value (TGI)	≈ 99.7	%	A375.S2 cells	Amelanotic melanoma

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	181	pM	A375.S2 cells	Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50)	260	pM	Calu-6 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	275	pM	PA-1 cells	Ovarian mixed germ cell tumor
Half Maximal Inhibitory Concentration (IC50)	319	pM	Hs 700T cells	Neoplasm
Half Maximal Inhibitory Concentration (IC50)	585	pM	NCI-H1703 cells	Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	767	pM	MDA-MB-468 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	910	pM	LN-229 cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	1447	pM	SW48 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 10	nM	Raji cells	EBV-related Burkitt lymphoma

Experiment 1 Reporting the Activity Date of This ADC					[2]
Patients Enrolled	Eligible participants include those with prostate adenocarcinoma (Part 1; prior ARAT therapy permitted) or select squamous/small cell carcinomas (Part 2; 1-2 prior therapies). Key exclusions involve excessive prior treatments, active CNS metastases, B7-H3 therapy history, or contraindications to corticosteroids. Archival tissue and measurable disease are required. Contraception and baseline organ function criteria apply.    Click to Show/Hide
Administration Dosage	MGC018 2.0, 2.7 mg/kg every 4 weeks
Related Clinical Trial
NCT Number	NCT05551117	Clinical Status	PHASE2
Clinical Description	A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Primary Endpoint	In Part 1, radiographic progression-free survival (rPFS) will be assessed every 8-12 weeks for up to 2 years using PCWG3 criteria, with a landmark 6-month rPFS analysis. In Part 2, objective response rate (ORR) will be measured by RECIST 1.1 based on confirmed complete (CR) or partial responses (PR).
Other Endpoint	Secondary endpoints include prostate-specific outcomes (PSA response, time to PSA progression, symptomatic skeletal events), tumor response metrics (ORR, duration of response, tumor size change), and safety (AEs, SAEs, immunogenicity). Assessments will be performed every 4-12 weeks per protocol-defined intervals.
Experiment 2 Reporting the Activity Date of This ADC					[3]
Patients Enrolled	Eligible patients must be ≥18 with platinum-refractory SCLC (including EGFR-mutant NSCLC-transformed SCLC), measurable disease (RECIST v1.1), ECOG 0-2, and adequate organ function. Key exclusions: untreated/symptomatic brain metastases, leptomeningeal disease, concurrent malignancies, or significant effusions. Women/men must adhere to strict contraception requirements. Archived/fresh tumor tissue is mandatory unless biopsy is medically unfeasible. Concurrent investigational agents or major surgery within 4 weeks pre-treatment are prohibited.    Click to Show/Hide
Administration Dosage	Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle
Related Clinical Trial
NCT Number	NCT06227546	Clinical Status	PHASE2
Clinical Description	A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Primary Endpoint	The primary efficacy endpoint is investigator-assessed Objective Response Rate (ORR) per RECIST v1.1, with tumor evaluations every 2 cycles (each 28 days) over 1 year.
Other Endpoint	Safety assessments include treatment-emergent adverse events (per CTCAE v5.0) from treatment start until 60 days post-last dose (~1 year). Secondary efficacy measures include Duration of Response (DOR), median PFS, 6-month PFS (both assessed via Kaplan-Meier over 1 year), and Overall Survival (OS) monitored for 3 years.
Experiment 3 Reporting the Activity Date of This ADC					[4]
Related Clinical Trial
NCT Number	NCT05551117	Clinical Status	Phase 2
Clinical Description	A phase 2, randomized, open-label, study of two dose levels of obramitamab duocarmazine in participants with metastatic castration-resistant prostate cancer.
Experiment 4 Reporting the Activity Date of This ADC					[5]
Patients Enrolled	Patients of multiple tumor types, which included 3 melanoma patients refractory to 2 prior lines of checkpoint therapy.
Administration Dosage	6 dose cohorts (0.50-4.00 mg/kg) every 3 weeks.
Related Clinical Trial
NCT Number	NCT03729596	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2, first-in-human, open-label, dose-escalation study of MGC018 (anti-B7-H3 antibody drug conjugate) alone and in combination with MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors.
Experiment 5 Reporting the Activity Date of This ADC					[6]
Related Clinical Trial
NCT Number	NCT05293496	Clinical Status	Phase 1
Clinical Description	A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with checkpoint inhibitor in participants with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.10%	High MET expression (MET+++; IHC H-score=265)
Method Description	Female Athymic Nude-Foxn1nu from Envigo (head and neck,triple-negative breast cancer models),68 weeks of age,were used for the PDX studies. Low passage tumor fragments were implanted into stock animals. When tumors reached 1.01.5 cm3,they were reimplanted into prestudy animals unilaterally on the left flank. When tumors reached an average tumor volume of 150-300 mm3,animals were matched by tumor volume into treatment or vehicle control groups. Three animals were assigned to each group and dosed intravenously by tail vein injection (10 mL/kg). Tumor volumes were measured twice weekly by calipers. Prostate cancer subcutaneous PDX model treated with MGC018 or control ADC at 3 mg/kg (QW3).    Click to Show/Hide
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-PAX-13565)
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.60%	Moderate MET expression (MET++; IHC H-score=130)
Method Description	Male NOG mice from Taconic (prostate cancer model),68 weeks of age,were used for the PDX studies. Low passage tumor fragments were implanted into stock animals. When tumors reached 1.01.5 cm3,they were reimplanted into prestudy animals unilaterally on the left flank. When tumors reached an average tumor volume of 150-300 mm3,animals were matched by tumor volume into treatment or vehicle control groups. Three animals were assigned to each group and dosed intravenously by tail vein injection (10 mL/kg). Tumor volumes were measured twice weekly by calipers. Head and neck cancer subcutaneous PDX model treated with MGC018 or control ADC at 3 mg/kg (Q2W 2).    Click to Show/Hide
In Vivo Model	Head and neck cancer PDX model
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.20%	High MET expression (MET+++; IHC H-score=240)
Method Description	Female Athymic Nude-Foxn1nu from Envigo (head and neck,triple-negative breast cancer models),68 weeks of age,were used for the PDX studies. Low passage tumor fragments were implanted into stock animals. When tumors reached 1.01.5 cm3,they were reimplanted into prestudy animals unilaterally on the left flank. When tumors reached an average tumor volume of 150-300 mm3,animals were matched by tumor volume into treatment or vehicle control groups. Three animals were assigned to each group and dosed intravenously by tail vein injection (10 mL/kg). Tumor volumes were measured twice weekly by calipers. Triple-negative breast cancer subcutaneous PDX model treated with MGC018 or control ADC at 3 mg/kg (QW2).    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer PDX model

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 22.40%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 0.3 mg/kg QWx4.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 30.10%	Moderate MET expression (MET++; IHC H-score=150)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). PA-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg as a single dose,QW1.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.90%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 43.90%	NegativeCD276 expression (CD276-)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). MDA-MB-468 triple-negative breast cancer orthotopic xenografts were treated with MGC018 or control ADC at 3 mg/kg.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 Luc cells		CVCL_0419
Experiment 5 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59.30%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 6 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 62.70%	Moderate MET expression (MET++; IHC H-score=150)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3).MDA-MB-468 triple-negative breast cancer orthotopic xenografts were treated with MGC018 or control ADC at 0.3 mg/kg QW4.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 Luc cells		CVCL_0419
Experiment 7 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 62.80%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). PA-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 0.3 mg/kg QW4.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 8 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.50%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 9 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.90%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 1 mg/kg QWx4.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 10 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.30%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 6 mg/kg.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 11 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.60%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A375.S2 melanoma subcutaneous xenografts were treated with MGC018 or control ADC at 0.3 mg/kg QW4.    Click to Show/Hide
In Vivo Model	Melanoma CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 12 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.80%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg QWx4.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 13 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.90%	High MET expression (MET+++; IHC H-score=265)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A375.S2 melanoma subcutaneous xenografts were treated with MGC018 or control ADC at 1 mg/kg.    Click to Show/Hide
In Vivo Model	Melanoma CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 14 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.50%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 10 mg/kg.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 15 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.80%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 6 mg/kg.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 16 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.50%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 10 mg/kg.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 17 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.40%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). PA-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg as a single dose,QW4.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 18 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.60%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). PA-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 1 mg/kg QW4.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 19 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.70%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 6 mg/kg.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 20 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97%	Moderate MET expression (MET++; IHC H-score=150)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3).MDA-MB-468 triple-negative breast cancer orthotopic xenografts were treated with MGC018 or control ADC at 1 mg/kg QW4.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 Luc cells		CVCL_0419
Experiment 21 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.60%	High MET expression (MET+++; IHC H-score=287)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). PA-1 ovarian cancer subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg as a single dose,Q2W4.    Click to Show/Hide
In Vivo Model	Ovarian cancer CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 22 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.90%	Moderate MET expression (MET++; IHC H-score=150)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). MDA-MB-468 triple-negative breast cancer orthotopic xenografts were treated with MGC018 or control ADC at 6 mg/kg.    Click to Show/Hide
In Vivo Model	Triple-negative breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 Luc cells		CVCL_0419
Experiment 23 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.10%	High MET expression (MET+++; IHC H-score=265)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A375.S2 melanoma subcutaneous xenografts were treated with MGC018 or control ADC at 3 mg/kg.    Click to Show/Hide
In Vivo Model	Melanoma CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 24 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.60%	High MET expression (MET+++; IHC H-score=255)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). Calu-6 lung cancer subcutaneous xenografts were treated with MGC018 or control ADC at 10 mg/kg.    Click to Show/Hide
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 25 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.70%	High MET expression (MET+++; IHC H-score=265)
Method Description	Human tumor cells (5x106) were resuspended in 1:1 medium (DMEM/F-12) and Matrigel basement membrane matrix (Corning) and implanted subcutaneously into the flank (A375.S2,Calu-6,PA-1) or mammary fat pad (MDA-MB-468) of mice. Mice were randomized into groups of 5-7 individuals per group. ADCs or vehicle control (PBS) were administered intravenously by tail vein injection (10 mL/kg) following growth of established tumors (100-150 mm3). A375.S2 melanoma subcutaneous xenografts were treated with MGC018 or control ADC at 1 mg/kg QW4.    Click to Show/Hide
In Vivo Model	Melanoma CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	181 pM	High CD276 expression (CD276+++; 138,000 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	260 pM	High CD276 expression (CD276+++; 139,000 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	275 pM	High CD276 expression (CD276+++; 310,000 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	319 pM	High CD276 expression (CD276+++; 122,000 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Neoplasm	Hs 700T cells		CVCL_0858
Experiment 5 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	585 pM	Moderate MET expression (MET++; IHC H-score=180)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 6 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	767 pM	Moderate CD276 expression (CD276++; 57,000 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 7 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	910 pM	Moderate CD276 expression (CD276++; 73,700 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Glioblastoma	LN-229 cells		CVCL_0393
Experiment 8 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1447 pM	High CD276 expression (CD276+++; 153,000 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 9 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10 nM	Moderate CD276 expression (CD276++; 59,800 CD276 molecules/cell)
Method Description	MGC018-mediated in vitro cytotoxicity was evaluated across a set of tumor cell lines representing multiple cancer types expressing varying levels of B7-H3. MDA-MB-468,A375.S2,PA-1,Calu-6,Hs700T,SW48,and LN-229 tumor cell lines were obtained from ATCC and cultured in DMEM/F-12 media containing 10% FBS. NCI-H1703 and Raji tumor cell lines were obtained from ATCC and cultured in RPMI1640 media containing 10% FBS.    Click to Show/Hide
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Ref 1	Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Ref 2	A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Ref 3	MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Ref 4	A Phase 2, Randomized, Open-label, Study of Two Dose Levels of Obramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer, NCT05551117
Ref 5	Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. J Clin Oncol. 2023 41:16_suppl, 7531-7531.
Ref 6	A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors, NCT05293496
Ref 7	Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19(11):2235-2244.